benzyl 2-hydroxy-5-formylbenzoate | 176047-66-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 2-hydroxy-5-formylbenzoate
• 英文别名: benzyl 5-formyl-2-hydroxybenzoate；benzyl 5-formyl-2-propoxybenzoate；benzyl 5-formylsalicylate；5-Formylsalicylic acid benzyl ester
• CAS: 176047-66-8
• 化学式: C₁₅H₁₂O₄
• 分子量: 256.258
• InChiKey: DTVOHZDGJLZMRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl 2-hydroxy-5-formylbenzoate 在 N-甲基吗啉 、 吡啶 、 4-二甲氨基吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 sodium chlorite 、 N-羟基-7-氮杂苯并三氮唑 、 sodium dihydrogenphosphate dihydrate 、 2-甲基-2-丁烯 、 水 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸酐 、 copper(II) oxide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 、 叔丁醇 为溶剂， 生成 tert-butyl 2-[2-[[1-[(2,4-dimethoxyphenyl)methylamino]isoquinolin-6-yl]carbamoyl]-6-oxo-1H-pyridin-3-yl]-5-(2,2-dimethylpropylcarbamoyl)benzoate
  参考文献：
  名称：

  Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold

  摘要：

  In this Letter, we describe the synthesis of several nonamidine analogs of biaryl acid factor VIla inhibitor 1 containing weakly basic or nonbasic P1 groups. 2-Aminoisoquinoline was found to be an excellent surrogate for the benzamidine group (compound 2) wherein potent inhibition of factor VIla is maintained relative to most other related serine proteases. In an unanticipated result, the m-benzamide P1 (compounds 21a and 21b) proved to be a viable benzamidine replacement, albeit with a 20-40 fold loss in potency against factor Vlla. (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.06.028
• 作为产物：
  描述：

  5-甲酰水杨酸 、 溴甲苯 在 potassium hydrogencarbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 以80%的产率得到benzyl 2-hydroxy-5-formylbenzoate
  参考文献：
  名称：

  设计，合成和体外评估一系列α-取代的苯丙酸PPARγ激动剂，以进一步研究立体化学与活性之间的关系

  摘要：

  我们先前证明，α-苄基苯丙酸型PPARγ-选择性激动剂6表现出相反的立体化学-活性关系，即与结构上相比，（R）-对映体比（S）-对映体是更有效的PPARγ激动剂。类似的α-乙基苯基丙酸型PPAR激动剂。在此，我们分别设计，合成和评估了旋光性α-环己基甲基苯基丙酸衍生物7和α-苯乙基苯基丙酸衍生物8。有趣的是，α-环己基甲基衍生物显示出立体化学-活性关系的逆转[即（R）比（S）]，就像α-苄基衍生物一样，而α-苯乙基衍生物表现出“正常”关系[（S）比（R）更有效。这些结果表明，相对于羧基而言，β位上存在支链碳原子是逆转立体化学-活性关系的关键决定因素。

  DOI：

  10.1016/j.bmc.2012.08.061

文献信息

• [EN] TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS<br/>[FR] DERIVES DE TETRAHYDROQUINOLINE UTILES EN TANT QU'INHIBITEURS DE SERINE PROTEASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004080971A1

  公开（公告）日：2004-09-23

  The present invention provides compounds of Formula (I) ; or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, B, L1, L2, X1, X2, X3, X4, R4, R5, R13, R14, R15 and R16 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物；或其立体异构体或药用可接受的盐形式，其中变量A、B、L1、L2、X1、X2、X3、X4、R4、R5、R13、R14、R15和R16如本文所定义。式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。具体而言，涉及选择性因子XIa抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• [EN] CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO<br/>[FR] CONJUGUÉS COMPRENANT DES GROUPES PEPTIDIQUES ET PROCÉDÉS ASSOCIÉS À CEUX-CI
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017089894A1

  公开（公告）日：2017-06-01

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体药物偶联物，包括：抗体；连接体；以及至少两个活性剂。在优选的实施例中，连接体包括由多个氨基酸组成的肽序列，其中至少两个活性剂通过共价键与氨基酸的侧链连接。抗体药物偶联物可以包括自焚基团，优选地是两个自焚基团。连接体可以包括O-取代的肟，例如，其中肟的氧原子被取代以与活性剂形成共价键连接；肟的碳原子被取代以与抗体形成共价键连接。
• Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors
  申请人：——

  公开号：US20040220206A1

  公开（公告）日：2004-11-04

  The present invention provides compounds of Formula (I): 1 or a stereoisomer or pharmaceutically acceptable salt or hydrate form thereof, wherein the variables A, B, L 1 , L 2 , X 1 , X 2 , X 3 , X 4 and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了Formula (I)的化合物：1或其立体异构体或药用可接受的盐或水合物形式，其中变量A、B、L1、L2、X1、X2、X3、X4和W如本文所定义。Formula (I)的化合物可作为凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂，例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。具体地，涉及具有选择性因子XIa抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用这些药物组合物治疗血栓栓塞性和/或炎症性疾病的方法。
• Tetrahydroquinoline derivatives as antithrombotic agents
  申请人：——

  公开号：US20030225110A1

  公开（公告）日：2003-12-04

  This invention relates generally to tetracyclic tetrahydroquinoline compounds, and analogues thereof, and pharmaceutically acceptable salt forms thereof, which are selective inhibitors of serine protease enzymes, especially factor VIIa; pharmaceutical compositions containing the same; and methods of using the same as anticoagulant agents for modulation of the coagulation cascade.

  这项发明通常涉及四环四氢喹啉化合物及其类似物，以及其药用盐形式，这些化合物是选择性抑制丝氨酸蛋白酶酶，特别是VIIa因子的；含有同样化合物的药物组合物；以及将其用作抗凝剂调节凝血级联的方法。
• Amidino derivatives and drugs containing the same as the active ingredient
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US06358960B1

  公开（公告）日：2002-03-19

  The novel amidino derivatives of the formula (I): wherein all the symbols are as in specification defined; have an inhibitory activity of a blood coagulation factor VIIa and are useful for treatment and/or prevention of several angiopathy caused by enhancing a coagulation activity, such as disseminated intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, peripheral arterial obstruction, thrombosis after artificial vascular transplantation and artificial valve transplantation, post-operative thrombosis, reobstruction and restenosis after coronary artery bypass operation, reobstruction and restenosis after PTCA or PTCR, thrombosis by extracorporeal circulation and procoagulative diseases such as glomerlonephriitis.

  该式(I)的胍基衍生物小说：其中所有符号均如规范中所定义；具有抑制血凝血因子VIIa的活性，并可用于治疗和/或预防由增强凝血活性引起的多种血管病，如弥散性血管内凝血、冠状动脉血栓形成、脑梗死、脑栓塞、短暂性缺血发作、脑血管疾病、肺血管疾病、深静脉血栓形成、周围动脉阻塞、人工血管移植后血栓形成和人工瓣膜移植后血栓形成、术后血栓形成、冠状动脉旁路手术后再阻塞和再狭窄、PTCA或PTCR后再阻塞和再狭窄、体外循环引起的血栓形成以及像肾小球肾炎这样的促凝病。